Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.
Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.
复制标题
DOI：
10.1016/j.jaccao.2022.04.002
复制
发表时间：
2022-06
影响因子：
11.1
通讯作者：
Libby, Peter
中科院分区：
文献类型：
--
作者：
Leiva, Orly;Hobbs, Gabriela;Ravid, Katya;Libby, Peter
关键词：
骨髓增生性肿瘤与血栓性并发症风险增加相关。这些疾病最常见的是基因中的体细胞突变，导致Janus相关激酶信号通路（例如Janus激酶2、钙网蛋白、骨髓增生性白血病蛋白）的组成性激活。这些基因中获得性功能获得性突变，特别是Janus激酶2，可导致一系列疾病，从不确定潜力的克隆性造血（最近认识到的心血管疾病的年龄相关促进因素）到坦率的血液恶性肿瘤。除血栓形成外，骨髓增生性肿瘤患者还可能发生其他心血管疾病，包括心力衰竭和肺动脉高压。作者综述了骨髓增生性肿瘤心血管并发症的病理生理机制，包括炎症、促血栓形成和促纤维化因子（包括转化生长因子-β和赖氨酰氧化酶）以及受影响个体的突变白细胞和血小板循环克隆的功能异常。抗炎治疗可能为骨髓增生性肿瘤患者提供心血管获益，这一假设需要在临床试验中进行严格评估。MPN会增加血栓形成和心血管风险。其中包括：动脉粥样硬化血栓形成、心力衰竭和肺动脉高压。在MPN中突变的基因包括一些在CHIP中发现的基因，也会增加心血管风险。炎症可能会增加MPN的心血管风险。在选定的MPN患者中进行抗炎治疗需要进行试验。
Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a recently recognized age-related promoter of cardiovascular disease, to frank hematologic malignancy. Beyond thrombosis, patients with myeloproliferative neoplasms can develop other cardiovascular conditions, including heart failure and pulmonary hypertension. The authors review the pathophysiologic mechanisms of cardiovascular complications of myeloproliferative neoplasms, which involve inflammation, prothrombotic and profibrotic factors (including transforming growth factor–beta and lysyl oxidase), and abnormal function of circulating clones of mutated leukocytes and platelets from affected individuals. Anti-inflammatory therapies may provide cardiovascular benefit in patients with myeloproliferative neoplasms, a hypothesis that requires rigorous evaluation in clinical trials. MPNs entail increased thrombotic and cardiovascular risks. Among them: atherothrombosis, heart failure, and pulmonary hypertension. Genes mutated in MPNs include some seen in CHIP, also raising cardiovascular risk. Inflammation likely contributes to increased cardiovascular risk in MPN. Anti-inflammatory therapy in selected MPN patients warrants testing.
登录
查看更多内容
影响因子：
3.5
作者：
Alvarez-Larran, Alberto;Arellano-Rodrigo, Eduardo;Cervantes, Francisco
通讯作者：
Cervantes, Francisco
DOI：
10.3324/haematol.2010.031070
发表时间：
2011-02-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Barbui, Tiziano;Carobbio, Alessandra;Rambaldi, Alessandro
通讯作者：
Rambaldi, Alessandro
癌症中的白细胞介素：从生物学到治疗。
DOI：
10.1038/s41568-021-00363-z
发表时间：
2021-08
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Briukhovetska D;Dörr J;Endres S;Libby P;Dinarello CA;Kobold S
通讯作者：
Kobold S
影响因子：
2.1
作者：
Corante, Noemi;Anza-Ramirez, Cecilia;Villafuerte, Francisco C.
通讯作者：
Villafuerte, Francisco C.
影响因子：
15.9
作者：
Chen, Pei-Yu;Qin, Lingfeng;Simons, Michael
通讯作者：
Simons, Michael